Novavax, Inc.

NASDAQ:NVAX   3:48:22 PM EDT
181.11
+6.70 (+3.84%)
Other Pre-Announcement

Novavax Announces Positive Data From Three Complementary Studies Of Covid-19 Beta (B.1.351) Variant Strain Vaccine

Published: 06/11/2021 20:20 GMT
Novavax, Inc. (NVAX) - Novavax Announces Positive Data From Three Complementary Studies of Covid-19 Beta (b.
1.351) Variant Strain Vaccine.
Novavax - Recombinant Spike Protein Antigen (rs-b.
1.351) Based on Beta (b.
1.351) Virus Lineage Highly Immunogenic in Mice and Produced Antibodies.
Novavax Inc - Humans Immunized With Nvx-cov2373 Showed Robust Antibody Responses to Original Sars-cov-2, As Well As Alpha and Beta Variant Strains.
Novavax Inc - Data Available Ahead of Publication Via Preprint Server, Biorxiv.
Novavax Inc - Primates Boosted With Rs-b.
1.351 Induced Strong Neutralizing Immune Response to Original Sars-cov-2, Alpha (b.
1.1.
7) and Beta Strains.
Novavax Inc - Expects to Initiate Further Clinical Testing of Rs-b.
1.351 in Fall of 2021.
Novavax - Data Show Vaccine Showed Strong Immunogenicity, Protection Against Both Alpha and Beta Variants.